| Autor: |
Strømme O; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7034 Trondheim, Norway., Heck KA; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7034 Trondheim, Norway., Brede G; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7034 Trondheim, Norway., Lindholm HT; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7034 Trondheim, Norway.; Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada., Otterlei M; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7034 Trondheim, Norway., Arum CJ; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7034 Trondheim, Norway.; Department of Urology, St. Olav's University Hospital, 7030 Trondheim, Norway. |
| Abstrakt: |
Bladder cancer (BC) diagnosis is reliant on cystoscopy, an invasive procedure associated with urinary tract infections. This has sparked interest in identifying noninvasive biomarkers in body fluids such as blood and urine. A source of biomarkers in these biofluids are extracellular vesicles (EVs), nanosized vesicles that contain a wide array of molecular cargo, including small noncoding RNA such as transfer RNA-derived fragments (tRF) and microRNA. Here, we performed small-RNA next-generation sequencing from EVs from urine and serum, as well as from serum supernatant. RNA was extracted from 15 non-cancer patients (NCPs) with benign findings in cystoscopy and 41 patients with non-muscle invasive BC. Urine and serum were collected before transurethral resection of bladder tumors (TUR-b) and at routine post-surgery check-ups. We compared levels of tRFs in pre-surgery samples to samples from NCPs and post-surgery check-ups. To further verify our findings, samples from 10 patients with stage T1 disease were resequenced. When comparing tRF expression in urine EVs between T1 stage BC patients and NCPs, 14 differentially expressed tRFs (DEtRFs) were identified. In serum supernatant, six DEtRFs were identified among stage T1 patients when comparing pre-surgery to post-surgery samples and four DEtRFs were found when comparing pre-surgery samples to NCPs. By performing a blast search, we found that sequences of DEtRFs aligned with genomic sequences pertaining to processes relevant to cancer development, such as enhancers, regulatory elements and CpG islands. Our findings display a number of tRFs that may hold potential as biomarkers for the diagnosis and recurrence-free survival of BC. |
